Filtered By:
Condition: Hemorrhagic Stroke
Drug: Pradaxa

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 307 results found since Jan 2013.

Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants
Abstract Atrial fibrillation (AF) is an important cause of preventable, disabling stroke and is increasingly prevalent with advancing age. As life expectancies increase around the world, AF-related stroke is a growing global public health concern. Most AF patients are elderly (≥75 years old) and increasing age is a consistent independent risk factor for AF-associated stroke. Warfarin anticoagulation is highly effective for stroke prevention in AF patients, but is underutilized especially in the elderly. Although elderly patients are at increased risk of hemorrhage with oral anticoagulants, the benefit for isch...
Source: Cardiology and Therapy - December 1, 2013 Category: Cardiology Source Type: research

Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat
This study assesses the risks and benefits of tissue plasminogen activator (tPA) treatment under oral anticoagulation with dabigatran compared with warfarin or vehicle control in transient middle cerebral artery occlusion (tMCAO). After pretreatment with warfarin (0.2 mg/kg/day), dabigatran (20 mg/kg/day), or vehicle (0.5% carboxymethyl cellulose sodium salt) for 7 days, tMCAO was induced for 120 min, followed by reperfusion and tPA (10 mg/kg/10 ml). Clinical parameters, including cerebral infarction volume, hemorrhagic volume, and blood coagulation, were examined. At 24 hr after reperfusion, markers for the neurovascular ...
Source: Journal of Neuroscience Research - November 17, 2013 Category: Neuroscience Authors: Syoichiro Kono, Kentaro Deguchi, Yoshio Omote, Taijun Yunoki, Toru Yamashita, Tomoko Kurata, Yoshio Ikeda, Koji Abe Tags: Research Article Source Type: research

Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation
Conclusion In this prospective observational study, anticoagulation with NOACs following AF catheter ablation was safe and effective at long-term follow-up. Fast onset of action makes NOACs especially attractive in patients without effective anticoagulation on admission and in patients following periprocedural complications.
Source: Europace - October 29, 2013 Category: Cardiology Authors: Eitel, C., Koch, J., Sommer, P., John, S., Kircher, S., Bollmann, A., Arya, A., Piorkowski, C., Hindricks, G. Tags: Ablation for atrial fibrillation Source Type: research

Dabigatran-related Intracerebral Hemorrhage Resulting in Hematoma Expansion
We present a case that suggests that hematoma expansion may occur after NOAC-related ICH.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2013 Category: Neurology Authors: Claus Z. Simonsen, Thorsten Steiner, Anna Tietze, Dorte Damgaard Tags: Case Reports Source Type: research

Letter by Kawada Regarding Article, "Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation" Letters to the Editor
Source: Stroke - September 23, 2013 Category: Neurology Authors: Kawada, T. Tags: Anticoagulants Letters to the Editor Source Type: research

Imaging of Contrast Medium Extravasation in Anticoagulation-Associated Intracerebral Hemorrhage With Dual-Energy Computed Tomography Basic Sciences
Conclusions— Dual-energy computed tomography allows quantifying CE, as a marker of ongoing bleeding, in a model of anticoagulation-associated ICH. Dabigatran induces less CE in ICH than warfarin and consequently reduces risks of hematoma expansion. This constitutes a potential safety advantage of dabigatran over warfarin. Nevertheless, in case of warfarin anticoagulation, prothrombin complex concentrates reduce this side effect.
Source: Stroke - September 23, 2013 Category: Neurology Authors: Won, S.-Y., Schlunk, F., Dinkel, J., Karatas, H., Leung, W., Hayakawa, K., Lauer, A., Steinmetz, H., Lo, E. H., Foerch, C., Gupta, R. Tags: Coumarins, Other anticoagulants, Other Treatment, Acute Cerebral Hemorrhage, Intracerebral Hemorrhage Basic Sciences Source Type: research

Anticoagulation in Patients with Dilated Cardiomyopathy, Low Ejection Fraction, and Sinus Rhythm: Back to the Drawing Board
Summary Heart failure patients present an important thrombo‐embolic risk, including symptomatic or silent peripheral arterial embolism, pulmonary embolism, and stroke. Patients in sinus rhythm who have concomitant depressed (<35%) left ventricular ejection fraction have a 4% rate of embolic events. Several prospective randomized trials of anticoagulation in this group of patients were either underpowered or had a short period of follow‐up. Even though in two studies warfarin had a slight advantage over aspirin (in the WATCH and WARCEF trials), it was at the cost of an increased risk in major hemorrhage. To decrease ...
Source: Cardiovascular Therapeutics - September 12, 2013 Category: Cardiology Authors: Alexandru Nicolae Mischie, Valentin Chioncel, Ionel Droc, Crina Sinescu Tags: Short communication Source Type: research

Causes of Death and Influencing Factors in Patients with Atrial Fibrillation: A Competing Risk Analysis from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study.
CONCLUSIONS: The majority of deaths are not related to stroke in a contemporary anticoagulated AF population. These results emphasize the need to identify interventions beyond effective anticoagulation, in order to further reduce mortality in AF. CLINICAL TRIAL REGISTRATION INFORMATION: http://www.clinicaltrials.gov. Identifier: NCT00262600. PMID: 24016454 [PubMed - as supplied by publisher]
Source: Circulation - September 9, 2013 Category: Cardiology Authors: Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom JW, Themeles E, Ezekowitz MD, Wallentin L, Yusuf S Tags: Circulation Source Type: research

Endovascular thrombectomy for acute ischemic stroke patients anticoagulated with dabigatran
For the treatment of acute ischemic stroke (AIS), IV recombinant tissue plasminogen activator (rtPA) has proven efficacy in eligible patients, but carries an increased risk of intracerebral hemorrhage . Preexisting anticoagulation, including the direct thrombin inhibitor dabigatran, usually contraindicates the use of rtPA. This notwithstanding, several single cases of IV rtPA treatment in patients with AIS under dabigatran have been reported, with mixed results . Endovascular therapy has emerged as a potential, yet still experimental, alternative treatment option for a number of clinical scenarios with contraindications to IV rtPA .
Source: Clinical Neurology and Neurosurgery - August 5, 2013 Category: Neurosurgery Authors: Petra Müller, Raffi Topakian, Michael Sonnberger, Karin Nußbaumer, Martin Windpessl, Veronika Eder, Hans-Joachim Nesser, Johannes Trenkler, Hans-Peter Haring Tags: Case reports Source Type: research

Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model
Conclusion: SD-W has the lowest C/U ratio among the 3 options. However, dabigatran might be considered as an alternative. GT-W is not C/U and should not currently be recommended for the routine anticoagulotherapy management of AF patients.
Source: Thrombosis Journal - July 17, 2013 Category: Hematology Authors: Léon NshimyumukizaJulie DuplantieMathieu GagnonXavier DouvilleDiane FournierCarmen LindsayMarc ParentAlain MilotYves GiguèreChristian GagnéFrançois RousseauDaniel Reinharz Source Type: research

Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation Clinical Sciences
Conclusions— Hemorrhagic stroke rates were higher on warfarin in Asians versus non-Asians, despite similar blood pressure, younger age, and lower international normalized ratio values. Hemorrhagic strokes were significantly reduced by DE in both Asians and non-Asians. DE benefits were consistent across Asian and non-Asian subgroups. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00262600.
Source: Stroke - June 24, 2013 Category: Neurology Authors: Hori, M., Connolly, S. J., Zhu, J., Liu, L. S., Lau, C.-P., Pais, P., Xavier, D., Kim, S. S., Omar, R., Dans, A. L., Tan, R. S., Chen, J.-H., Tanomsup, S., Watanabe, M., Koyanagi, M., Ezekowitz, M. D., Reilly, P. A., Wallentin, L., Yusuf, S., the RE-LY In Tags: Other anticoagulants, Embolic stroke Clinical Sciences Source Type: research

The Long Term Multi-Center Observational Study of Dabigatran Treatment in Patients with Atrial Fibrillation: (RELY-ABLE) Study.
CONCLUSIONS: During 2.3 years continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily compared to 110 mg, and similar rates of stroke and death. CLINICAL TRIAL REGISTRATION INFORMATION: Clinicaltrials.gov; Identifier: NCT00808067. PMID: 23770747 [PubMed - as supplied by publisher]
Source: Circulation - June 14, 2013 Category: Cardiology Authors: Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom JW, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn Tags: Circulation Source Type: research

Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
Atrial fibrillation (AF) is an independent risk factor for ischemic stroke occurrence, severity, recurrence, and mortality. Anticoagulation therapy for the prevention of thromboembolism is critical in patients with AF who are at risk of stroke. Warfarin has been an efficacious anticoagulant for this purpose, but its use has been limited by frequent laboratory monitoring, drug interactions, unpredictable individual response, delayed onset of action, and bleeding. Apixaban is the second oral direct selective factor Xa inhibitor approved for the prevention of stroke/systemic embolism in patients with nonvalvular AF. It was si...
Source: Cardiology in Review - June 6, 2013 Category: Cardiology Tags: New Therapy Update Source Type: research

Dabigatran, intracranial hemorrhage, and the neurosurgeon.
Abstract Dabigatran etexilate (Pradaxa) is a novel oral anticoagulant that has gained FDA approval for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In randomized trials, the incidence of hemorrhagic events has been demonstrated to be lower in patients treated with dabigatran compared with the traditional anticoagulant warfarin. However, dabigatran does not have reliable laboratory tests to measure levels of anticoagulation and there is no pharmacological antidote. These drawbacks are challenging in the setting of intracerebral hemorrhage. In this article...
Source: Neurosurgical Focus - May 1, 2013 Category: Neurosurgery Authors: Awad AJ, Walcott BP, Stapleton CJ, Yanamadala V, Nahed BV, Coumans JV Tags: Neurosurg Focus Source Type: research

Reservations against new oral anticoagulants after stroke and cerebral bleeding
Abstract: Dabigatran, rivaroxaban, and apixaban are the new oral anticoagulants (NOAC) which have been investigated in patients with atrial fibrillation (AF) for primary and secondary prevention of stroke and thromboembolism. In these trials NOAC had a similar efficacy and safety profile compared to traditional vitamin-K-antagonists such as warfarin. We advise caution in the use of NOAC in patients with stroke or cerebral hemorrhage because of the following reasons:1) Patients with cerebral bleeding were excluded from the trials. 2) Stroke within 14days and severe stroke within 6months before screening were exclusion crite...
Source: Journal of the Neurological Sciences - April 29, 2013 Category: Neurology Authors: Claudia Stöllberger, Josef Finsterer Tags: Opinion Source Type: research